LOXL2 and pancreatic adenocarcinoma: In patients with CESC, PAAD, BLCA, LUAD, MESO, LGG, UVM, and LIHC, elevated LOXL2 expression indicated decreased survival time according to Kaplan–Meier survival analysis (Fig. 2A), and non-significant correlations were shown in Figure S2.